Endovia Health Sciences宣布，其有意在美国食品药品监督管理局（FDA）的“次要用途/次要物种”（Minor Use / Minor Species，MUMS）认定框架下，推动相关产品的研发工作，并计划采用该机构设定的附条件批准路径。
这一战略方向意味着，Endovia Health Sciences将寻求通过FDA专门针对有限市场需求的兽药或人用药物所设立的加速审评通道，从而在满足未竟医疗需求的同时，降低传统审批流程中的时间与成本壁垒。
公司方面表示，该决定是基于对当前监管环境的深入评估，并旨在借助MUMS条款所提供的激励措施，包括潜在的七年市场独占权，来加快候选产品的临床开发及上市进程。
附条件批准途径则允许企业在获得初步疗效数据后，先行获取市场准入资格，后续再补充确证性研究资料。此举有望为那些在主要物种或常见适应症之外、但仍具重要意义的治疗方案，开辟更为务实的落地通道。
Endovia Health Sciences尚未披露具体的候选产品细节，但明确表达了其致力于在这一特殊监管框架内，探索并推进创新疗法的坚定意向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.